ASND
NASDAQAscendis Pharma A/S
Ascendis Pharma A/S (ASND) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for ASND, including 6 SEC filings, 4 press releases and news items and 2 earnings updates. The most recent was published Nov 12, 2026.
ASND rankings
Financial highlights
Full financials- Revenue, FY2025
- €720.13M
- Revenue growth
- +98.0%
- Net income, FY2025
- -€228.03M
- Net margin
- -31.7%
- Cash
- €616.04M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks62+83%
2026-05-172026-11-08
Mix3490d
- Other13(38%)
- SEC Filings11(32%)
- Insider4(12%)
- Analyst3(9%)
- Earnings2(6%)
- 13D/G1(3%)
Activity · 52 weeks13680 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis Pharma Reports Third Quarter 2026 Financial ResultsQ3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH®, €59 million for SKYTROFA®, and €16 million for YUVIWEL® Received positive CHMP and COMP opinions recommending EU marketing authorization and maintenance of orphan medicinal product designation for TransCon® CNP Final EC decision for TransCon CNP expected in Q4 2026; first EU launch planned in Germany in Q1 2027Presented Week 52 sentinel cohort data in infants with achondroplasia aged 0 to <2 years showing TransCon CNP stabilized or improved foramen magnum stenosis, and increased linear growth; topline pivotal data expected Q3 2027Conference call today at 8:00 a.m. ET COPENHAGEN, Denmark, Nov. 12,
- PRAscendis Pharma to Participate in the Jefferies London Healthcare ConferenceCOPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 17, 2026, at 11:30 a.m. Greenwich Mean Time (GMT) / 6:30 a.m. Eastern Time / 3:30 a.m. Pacific Time in London, United Kingdom. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company f
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PROnce-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) as a treatment for achondroplasia in children. The designation would provide Ascendis benefits that include 10 years of orphan market exclusivity upon final adoption of the COMP opinion by the European Commission (EC). The opinion follows the EMA’s Committee for Medicinal Products for Huma
- PRAscendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026COPENHAGEN, Denmark, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report third quarter 2026 financial results and provide a business update on Thursday, November 12, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast at 8:00 a.m. Eastern Time (ET) that day to discuss its third quarter 2026 financial results and business update. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at http
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/SSCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRTransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 YearsCOPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide) for up to 5 years in the Company’s Phase 2 PaTH Forward and Phase 3 PaTHway trials. Results from the pooled analysis were shared in a poster presented by nephrologist Elvira Gosmanova, M.D., Professor of Medicine at Albany Medical College, during Kidney Week 2026, the annual meeting of the American Society of Nephrology. "These groundbreaking improvements in renal function underscore the unique ability of T
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PROnce-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in ChildrenCOPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma’s Marketing Authorisation Application (MAA) is expected during Q4 2026. "We are pleased to receive this positive opinion reflecting the unique profile of TransCon CNP," said Jan Mikkels
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon® PTH (palopegteriparatide) over a 5-year period. "Our growing body of clinical trial data continues to illustrate th
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- INSIDERSEC Form 4 filed by Director Bienaime Jean Jacques4 - Ascendis Pharma A/S (0001612042) (Issuer)
- ANALYSTAscendis Pharma downgraded by Raymond James with a new price targetRaymond James downgraded Ascendis Pharma from Strong Buy to Outperform and set a new price target of $287.00
- PRAscendis Announces Planned $400 Million Share Repurchase ProgramCOPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program). Purchases under the planned Share Repurchase Program may be made from time to time, in such amounts as management deems appropriate, through a variety of methods, which may include open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, purchases through 10b5-1 trading plans, or by any combination of such methods. The timing and amount of any repurchases pursuant to the Share
- PRAscendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows termination of the collaboration agreement between Ascendis and Novo Nordisk A/S announced in November 2024. Under the terms of the agre
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- INSIDERSVP & PAO Bodenhoff Mads exercised 3,000 units of Ordinary Shares at a strike of $110.00 and sold $810,570 worth of Ordinary Shares (3,000 units at $270.19) (SEC Form 4)4 - Ascendis Pharma A/S (0001612042) (Issuer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRFirst Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in ACH-specific supine length Z-score of +0.42 from baseline through Week 52 – Treatment with TransCon CNP was generally well tolerated, with no reports of injection site reactions over the 52-week treatment period COPENHAGEN, Denmark, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced Week 52 data from the open-label sentinel cohort portion of the reACHin Trial (which preceded the now fully enrolled double-blinded portion of the trial) sho
- PRAscendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceCOPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time in New York, New York. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying our i
ASND FAQ
11 questionsWhat does Ascendis Pharma A/S do?
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup...What is the latest news on ASND?
In the last 30 days Quantisnow tracked 13 wire items for ASND: 6 SEC filings, 4 press releases and news items, 2 earnings updates and 1 13D/G filing. The most recent was published on November 12, 2026.What is ASND revenue?
Ascendis Pharma A/S (ASND) reported €720.13M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 98.0% from the year before.Is ASND profitable?
No. Ascendis Pharma A/S reported a net loss of €228.03M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ASND have?
Ascendis Pharma A/S reported €616.04M in cash and cash equivalents and €385.25M of debt on its most recent balance sheet in SEC filings.Where does ASND stock trade?
Ascendis Pharma A/S (ASND) is listed on NASDAQ.What sector and industry is ASND in?
Ascendis Pharma A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ascendis Pharma A/S go public?
Ascendis Pharma A/S (ASND) completed its IPO in 2015.What are analysts saying about ASND?
Across the last 8 analyst actions on Ascendis Pharma A/S, there were 0 upgrades and 1 downgrade. The most recent action was from Raymond James: Outperform with a $287.00 price target on 2026-09-15. Recent price targets range from $255.00 to $355.00.What companies are similar to ASND?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare ASND side-by-side with any of them on Quantisnow.How can I track ASND on Quantisnow?
Quantisnow aggregates Ascendis Pharma A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASND to receive live email and push alerts on every new disclosure.